This company has been marked as potentially delisted and may not be actively trading. NASDAQ:SVA Sinovac Biotech (SVA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsDividendFDA EventsHeadlinesOptions ChainOwnershipTrendsBuy This Stock About Sinovac Biotech Stock (NASDAQ:SVA) 30 days 90 days 365 days Advanced Chart Get Sinovac Biotech alerts:Sign Up Key Stats Today's Range$6.47▼$6.4750-Day Range$6.47▼$6.4752-Week Range$5.73▼$8.75VolumeN/AAverage VolumeN/AMarket Capitalization$644.67 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China. Read More Receive SVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sinovac Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address SVA Stock News HeadlinesSINOVAC Board Sets the Record Straight on July 8 Special Meeting of ...July 13, 2025 | morningstar.comMSINOVAC Board of Directors Provides Update on Status of US$55.00 ...July 11, 2025 | morningstar.comMTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes. | Porter & Company (Ad)SINOVAC Board Sets the Record Straight on July 8 Special Meeting of ShareholdersJuly 11, 2025 | businesswire.comSinovac Biotech’s New Board Charts Future Path with Strategic InitiativesJuly 11, 2025 | tipranks.comNewly Elected Directors of Sinovac Hold the First Board MeetingJuly 10, 2025 | financialpost.comFNewly Elected Directors of Sinovac Hold the First Board MeetingJuly 10, 2025 | businesswire.comFinal Reminder for SINOVAC Shareholders to Vote the WHITE Proxy Card "AGAINST" Misguided Proposals 1 and 2 - NasdaqJuly 9, 2025 | nasdaq.comSee More Headlines SVA Stock Analysis - Frequently Asked Questions Who are Sinovac Biotech's major shareholders? Top institutional investors of Sinovac Biotech include Vivo Capital LLC (5.92%), California Public Employees Retirement System (0.07%), Skandinaviska Enskilda Banken AB publ (0.04%) and Spark Investment Management LLC (0.03%). View institutional ownership trends. What other stocks do shareholders of Sinovac Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sinovac Biotech investors own include Pfizer (PFE), Tesla (TSLA), AT&T (T), Exxon Mobil (XOM), Abbott Laboratories (ABT), Bristol Myers Squibb (BMY) and Johnson & Johnson (JNJ). Company Calendar Record date for 7/7 Dividend5/23/2025Dividend Payable7/07/2025Ex-Dividend for 7/7 Dividend7/08/2025Today8/25/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryN/A Current SymbolNASDAQ:SVA CIK1084201 Webwww.sinovac.com Phone86-10-5693-1800Fax86-10-5693-1800Employees3,261Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$448.27 million Price / Sales1.44 Cash Flow$0.17 per share Price / Cash Flow38.95 Book Value$120.83 per share Price / Book0.05Miscellaneous Outstanding Shares99,640,000Free Float86,894,000Market Cap$644.67 million OptionableOptionable Beta0.61 The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:SVA) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sinovac Biotech, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sinovac Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.